Navigation Links
Transdel Pharmaceuticals to Present at Two Investor Conferences
Date:10/20/2009

LA JOLLA, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced that Dr. Juliet Singh, President and Chief Executive Officer of Transdel, will present a company overview at two upcoming conferences.

Dr. Singh will present at the 4th annual BIOCOM Investor Conference in San Diego, CA on Monday, October 26, 2009 at 4:00 p.m., PDT (7:00 p.m., EDT). Dr. Singh will also present at the 8th Annual BIO Investor Forum in San Francisco, CA on Thursday, October 29, 2009 at 12:30 p.m., PDT (3:30 p.m., EDT).

Interested parties can access a live audio webcast of the BIO Investor Forum presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel®, the Company's lead pain product, has successfully completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel(TM) platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. In June 2009, the Company announced that they entered into a license agreement with JH Direct, LLC for the exclusive worldwide rights to Transdel's anti-cellulite cosmeceutical product which utilizes the Company's Transdel(TM) technology. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel(®); the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the final analyses of the data from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel(®) before the Company can submit a 505(b)2 NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel(®); and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Transdel Pharmaceuticals, Inc.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transdel Pharmaceuticals Closes $4 Million Financing
2. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
3. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... and WASHINGTON , March 28, ... provider, GENEWIZ, will launch single-cell sequencing during the American Association ... E. Washington Convention Center in Washington, D.C. ... to perform differential gene expression of thousands of cells ... Experts on-hand at AACR ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... international life sciences corporation Anpac Bio-Medical Science ... a new, international record, processing and reporting over ... "Cancer Differentiation Analysis" (CDA) liquid biopsy tests. ... Nobel Prize Laureate Summit publications, Anpac Bio,s CDA ...
(Date:3/28/2017)... , March 28, 2017 ... and unpredictable sector due to the scientifically intensive ... include medical, agricultural, environmental, and industrial. In today,s pre-market ... Portola Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: ... Therapeutix Inc. (NASDAQ: OCUL ). Learn ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Harvill as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished ... and operations. , Avomeen is a leader in a wide range of ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):